Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

6 trials 3 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

2 Completed trials

14 Countries active

20 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 4 Phase II: 2

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Astrocytoma malignant 1 Prostate cancer 1 Meningioma 1 Hormone receptor positive HER2 negative breast cancer 1

Top IMPs

LUTETIUM (177LU) OXODOTREOTIDE 1 LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN 1 VORASIDENIB 1

All trials

6 total

EORTC 2237-BCG-QLG: Improvement of Quality of Life through supportive treatments for Endocrine Therapy – related symptoms in patients with e… Not authorised

2024-513442-10-00 Phase III 5 countries
Radiopharmaceutical treatment of advanced kidney cancer Recruiting

2024-517899-38-00 Phase II 3 countries LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting

2024-519404-27-00 Phase III 8 countries VORASIDENIB
Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting

2024-513443-93-00 Phase II 8 countries LUTETIUM (177LU) OXODOTREOTIDE
A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-ris… Ended

2024-513450-30-00 Phase III 3 countries
EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit… Ended

2024-513509-30-00 Phase III 8 countries

Showing 1–6 of 6 trials

← All sponsors A–Z